Cognitive Function in Athletes Cleared for Return-to-Play After Sport-Related Concussion (Cog-RTP)

November 19, 2026 updated by: Kayla Covert, Baylor Research Institute

Cognitive Function in Athletes Cleared for Return-to-Play After Sport-Related Concussion (Cog-RTP)

The purpose of this study is to determine whether a brief, objective cognitive assessment can detect exercise-induced changes in cognitive performance in adolescent athletes who have been medically cleared for return-to-play following sport-related concussion.

Study Overview

Status

Not yet recruiting

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Texas
      • Frisco, Texas, United States, 75034
        • Baylor Scott & White Sports Therapy & Research at the Star
        • Contact:
        • Principal Investigator:
          • Kayla Covert, DPT

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

12 years to 18 years (Child, Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • 12-18 years old
  • Actively engaged in organized sports activities within the past 12 months
  • Completed RTP (Return-to-Play) testing within the past 30 days

Exclusion Criteria:

  • History of ocular or muscular spasms
  • History of epileptic seizures
  • History of fainting or loss of consciousness triggered by flashes of light, patterns, or exposure to infrared light sources (e.g., eye tracker)
  • History of eye surgery and lenses implanted with different prescriptions in each eye
  • History of ptosis (drooping eyelids)
  • Taking medications that cause pupil dilation
  • Active concussion symptoms
  • Cardiovascular, respiratory, or neurological conditions contraindicating exertion
  • Orthopedic or neurologic, or other limitations
  • History of moderate or severe traumatic brain injury (GCS ≤12)
  • Uncontrolled asthma
  • Limited English proficiency

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Screening
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Adolescents following medical clearance from concussion

Participants will undergo a supervised, 30-minute, moderate-intensity, bodyweight workout with a warm-up and a cool down.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cognitive performance
Time Frame: Baseline (pre-exercise) and immediately post-exercise during the single study visit

Cognitive performance measured before and immediately after standardized exercise during a single study visit. Cognitive domains assessed include Processing Speed, Executive Function, Working Memory, Short-Term Memory, Sustained Attention, Selective Attention, and Spatial Perception.

Baseline (pre-exercise) and immediately post-exercise during the single study visit

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Rivermead Post Concussion Questionnaire 3 (RPQ-3)
Time Frame: baseline, pre-intervention

The RPQ-3 assesses the severity of three post-concussion symptoms: headache, dizziness, and nausea. Each item is scored on a scale of 0-4, with a total score ranging from 0 to 12. Higher scores indicate greater post-concussion symptom severity (worse outcomes).

baseline, pre-intervention
Pediatric Quality of Life Inventory Short Form 15 (PedsQL 4.0 SF-15)
Time Frame: baseline, pre-intervention

The PedsQL 4.0 SF-15 assesses health-related quality of life in children and adolescents across four domains: physical functioning, emotional functioning, social functioning, and school functioning. The 15 items are rated on a 5-point Likert scale (0-4) and reverse-scored and linearly transformed to a 0-100 scale. The total score ranges from 0 to 100, with higher scores indicating better health-related quality of life (better outcomes).

baseline, pre-intervention
Brief Pittsburgh Sleep Quality Index (B-PSQI)
Time Frame: baseline, pre-intervention

The B-PSQI assesses sleep quality over the past month across seven domains: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction. The six items are scored on a scale of 0-3, with a total score ranging from 0 to 18. Higher scores indicate poorer sleep quality (worse outcomes).

baseline, pre-intervention
Vestibular/Oculomotor Motor Screening (VOMS)
Time Frame: baseline, pre-intervention

The VOMS assesses vestibular and ocular motor symptom provocation following concussion. The assessment includes smooth pursuits, horizontal and vertical saccades, near point of convergence, vestibulo-ocular reflex (VOR), and visual motion sensitivity (VMS). Participants rate four symptoms (headache, dizziness, nausea, and fogginess) on a scale of 0-10 before and immediately after each task. The total symptom score ranges from 0 to 280, with higher scores indicating greater symptom severity (worse outcomes). Symptom provocation is also assessed by calculating the change in symptom ratings from baseline.

baseline, pre-intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

October 30, 2027

Primary Completion (Estimated)

September 30, 2029

Study Completion (Estimated)

December 1, 2029

Study Registration Dates

First Submitted

October 29, 2026

First Submitted That Met QC Criteria

November 19, 2026

First Posted (Actual)

November 20, 2026

Study Record Updates

Last Update Posted (Actual)

November 20, 2026

Last Update Submitted That Met QC Criteria

November 19, 2026

Last Verified

October 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Aggregated and anonymized study findings will be reported in scientific publications. De-identified data will be shared with collaborators as specified in data use agreements after institutional review and approval.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe